# The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

> **NCT06439693** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 72 (estimated)

## Conditions studied

- Breast Cancer Female
- Breast Cancer
- Breast Cancer Metastatic
- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Nab-Paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Phesgo
- **DRUG:** T-DM1
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** Trastuzumab Subcutaneous Subcutaneous
- **DRUG:** Tucatinib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT06439693
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2030-03-30
- **Final completion:** 2033-03-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439693, "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06439693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*